Redlands, CA -- (ReleaseWire) -- 06/03/2022 -- Weed delivery in California just got even easier with the merger of two of the most reputable and beloved weed delivery companies, Cali Care Group and Mary Daze. The collaboration will expand delivery service areas as well as cannabis product options for each company which will now be operating under the delivery site Ilovemyweed.com.

Mary Daze is a discrete weed delivery service loved by its customers for its prompt and professional weed delivery in many parts of California. Their focus has been on providing the fastest high-quality weed delivery service with an average order of cannabis or cannabis products taking only 30 minutes.

Cali Care Group was established by Joe Reed in 2010 when Joe noticed that the cannabis medical market wasn't offering a "Customer First" approach. This was when the word "Care" was added to the name.

The merging of Mary Daze and Cali Care Group marks a new era for marijuana delivery in California, combining all of the most loved cannabis brands and products under one roof with the best delivery times in the state. The areas that the new ILOVEMYWEED.COM site will be able to service are expected to increase, allowing more Californians to be able to order quality cannabis and cannabis products to be delivered right to their doorstep.

As the two weed delivery companies join forces, new and existing customers can still expect to have access to the best weed brands and a wide range of weed products which they can order online or via phone and have their order delivered to them in record times to any of the serviceable areas.

Customers will be able to buy several named brands of high-quality marijuana, CBD, cannabis concentrate, edibles, and various cannabis accessories. Weed delivery right to your door discreetly and professionally with payment options to suit your needs is what new and existing customers can expect – more of the same but better, thanks to greater coverage and more marijuana and marijuana products on offer.

Quality control is of the utmost importance for the newly merged group. The company sources only the best weed and weed products for their customers to enjoy. They understand the need for choice, allowing customers with any budget or taste to find what they are looking for. The premium weed delivery service is sure to become a crowd favorite and the leading weed delivery service with the combined expertise of Mary Daze and Cali Care Group.

Customers outside of California are able to order many of the products available on the I Love My Weed online weed store with some limitations depending on the state or international law. As the weed company continues to expand its weed delivery operations and product lines, the ultimate winners from this merger will surely be the consumers.

For anyone who appreciates the finest weed and most famous weed brands or wants to stock up on weed accessories, ILOVEMYWEED.COM can deliver all of that and more quickly, discreet, and professionally. Call (951) 662-6204 or visit their online store.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The pandemic has forced many elective surgeries to be cancelled or postponed. Can we expect a rebound in 2021? How have average selling prices changed over the last year? iData Research brand-analysis service is finding the answers.

Vancouver, BC -- (ReleaseWire) -- 12/16/2020 -- iData Research is engaging custom solutions to support customers with questions related to the pandemic's impact on healthcare markets. Analysis of products, such as those used for breast reconstruction and hernia repair exemplifies the current scenario showing 80% of the 18 companies analyzed are, for instance, showing an average of 36% sales decrease in Q2'20 relative to Q2'19, with 43% seeing more than one million dollars drop in quarterly revenue.

iData's MedSKU brand-level analysis provides up-to-date data on average selling prices, units sold, revenue and market shares of all of the top-performing and emerging products in the US market by SKU (stock keeping unit). It empowers healthcare companies with insights into the market dynamics, answering top-of-mind questions arising from the current economic scenario like revenue impact, changes in average selling prices and overall brand performance. The SKU-level data and product information allows users to also run their independent analysis by "slicing and dicing" the market to get direct product comparisons.

"There's both an economic and strategic imperative for healthcare companies to review their plans, recognizing that the impact of the pandemic now requires better informed and data-driven decisions," said Dr. Kamran Zamanian, CEO of iData Research. "The findings deriving from MedSKU are a unique way to identify and address what is really happening in the market."

While the market leaders AbbVie (Allergan) and Becton Dickinson (C.R. Bard) still hold a significant share of the market, the MedSKU analysis shows smaller companies and brands capturing market share gains.

Information from MedSKU has also provided valuable insights into price changes and trends. The analysis for US breast reconstruction and the US hernia repair market showed that 16% of the SKUs had a price increase larger than 5% in Q2'20 relative to Q2'19. Meanwhile, only 7% had a 5% or more price drop when compared to 2019 average selling prices.

Find out more at:

www.idataresearch.com/medsku

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Los Angeles, CA -- (ReleaseWire) -- 10/20/2020 -- To help raise awareness about stomach cancer and the devastating effects it can have on the lives of patients and their families, Hope for Stomach Cancer is hosting an interactive webinar with a cancer survivor and four esteemed physicians who are specialists in this terrible disorder. "Surgical Strategies for Stage IV Stomach Cancer" will explore PIPAC, HIPEC, and IP chemo for late stage cancer patients. It will take place online on November 7, 2020 between 10 am and 11:30 and PST. The event is free, but registration is required at www.HopeWebcast.org.

"This is our inaugural webcast," said Aki Smith, Founder and Executive Director of Hope for Stomach Cancer. "It's part of a series of Hope webcasts that are designed to share treatments for this disease at every stage. By sharing treatment information with both patients and physicians, we hope to improve survivability and comfort."

This event will include some of the nation's most respected surgeons and oncologists:

– Moderator: Dr. Samuel Klempner, Massachusetts General Hospital
– Dr. Andrew M. Blakely, National Cancer Institute
– Dr. Yanghee Woo, City of Hope
– Dr. Brain D. Bagwell, MD Anderson Cancer Center

The event will also feature Lexy Patton, a 27-year-old cancer patient who was only given months to live in February 2020. Lexy's story is a powerful testament to the work that needs to be done for Stage IV stomach cancer patients around the world.

Every November, many organizations like Hope for Stomach Cancer, work to raise awareness of this deadly disease. Each year, 27,600 cases of stomach cancer are diagnosed in the US alone. With an overall survivability rate of just 31 percent (just 5 percent for Stage IV patients), stomach cancer is one of the deadliest. While overall incidents of stomach cancer have dropped in recent decades, incidents in young victims are on the rise for reasons unknown.

This disease disproportionately affects minorities, with African-American men 2.5 times more likely and African-American women 2.2 more likely to die from it than their non-Hispanic white counterparts.

Worldwide, over 700,000 people die annually from stomach cancer making it the third-leading cancer-specific killer.

"Hope for Stomach Cancer is sponsoring this event to help bring patients and doctors more information and more weapons to fight this terrible disease," Smith said. "The Hope Webinar Series will deliver hope to everyone affected by this disease. We work to deliver awareness all year long with November being the time when there is a national awareness drive."

This educational event is being sponsored in part by Bristol-Myers Squibb, Taiho Oncology and Daiichi-Sankyo. Hope for Stomach Cancer is grateful to their sponsors, their guests, and all their volunteers for giving hope to those with stomach cancer worldwide.

Hope for Stomach Cancer is a 501(c)(3) that provides resources to patients, caregivers and loved ones while promoting early detection and prevention to the general and medical communities. Hope creates and facilitates programs that enable those affected by stomach cancer to take actionable steps to live the best possible life through each phase of the disease. Their Vision: Bridge the Gap between Research and Patient Care.

For more information about this topic or for sponsorship opportunities, please contact Aki Smith at 424-239-9943 or email at aki@stocan.org.

To Register: https://zoom.us/webinar/register/3016028845990/WN_OQRFBww_T4--qfBeEWhpQw

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Rochester, NY -- (ReleaseWire) -- 05/28/2020 -- While Anixa Biosciences (NASDAQ:ANIX) has gained some visibility for their recent work on Covid-19, it's important to understand that that company has some additional compelling assets. Today, I want to discuss their breast cancer vaccine program. I wont discuss all the market size details about breast cancer as most of us know that breast cancer is the most common cancer diagnosed in women in the US and throughout the world. The most dangerous type of breast cancer is something called, triple negative breast cancer (TNBC). It is called TNBC because the cancer is negative for hormone receptors as well as Her2neu, a marker for a type of breast cancer. Because it does not have those receptors, TNBC grows rapidly without growth signals provided by the proteins that bind to those receptors. Roughly on quarter of all breast cancers are TNBC, but because of its aggressiveness and lack of good therapies for TNBC, it is the cause of roughly half of breast cancer mortality.

Women who have mutations in their in genes known as BRCA genes, are at high risk of getting breast cancer in their lifetimes and typically the type of cancer they get is TNBC. Because of these facts, many women are choosing to have their breasts and ovaries removed even though they are healthy. They have chosen to not take the chance of the cancer ever developing as they might die. This is a bid decision for a woman, as it is a painful, risk-laden, expensive and disfiguring surgery. The most famous case of a woman opting for this surgery is that of mega-actress Angelina Jolie having her breasts ovaries removed. Since she was positive for the BRCA mutations and members of her family had suffered and died of breast cancer, she chose the surgery before she had cancer.

With that context, what is Anixa doing about this? Anixa is developing a breast cancer vaccine that could eventually eliminate TNBC, as well as other cancers. This vaccine was invented at the Cleveland Clinic, which is one of the top research hospitals in the country (as a fun exercise, if you Google the "best hospitals in the US", the Cleveland Clinic always comes out as number 1 or 2, regardless of who is making that list). A brilliant immunologist identified a protein that shows up in the mammary glands when a woman is lactating, after giving birth to a child. When the woman stops lactating, the protein disappears until the next child is born. If the woman is not giving birth anymore, the protein is gone UNTIL the woman develops breast cancer, including TNBC. This immunologist discovered that the protein shows up again when breast cancer occurs. He and is research team postulated that if they could immunize women against this protein (by making a vaccine) they might eliminate the onset of breast cancer. This research has been ongoing at the Cleveland Clinic for over a decade.

The animal studies showed that this vaccination approach eliminated the onset of breast cancer in 100% of the mice that were immunized. Anixa licensed this technology and is working with the Cleveland Clinic to take this vaccine through human testing and eventual FDA approval. We have to understand that no matter how good the animal data is, there is always risk that it will not work in humans, so we have to see what the human data says. Anixa and the Cleveland Clinic hope to take this vaccine into human testing by the end of 2020. There is a team at the Cleveland Clinic working with Anixa to conduct the human trials. Imagine if this works in humans as well as it did in animals. Women would just have to get a shot and may never have to worry about breast cancer. The market opportunity is massive in the US and worldwide. The impact on women would be tremendous and the economic value to the healthcare system would be equally impactful. In addition, all of these facts, including the compelling scientific data, enabled the Cleveland Clinic to get a Department of Defense grant to fund this program all they way up to completion of two Phase 1 trials. If the data in the funded trials look positive, maybe the government will fund the Phase 2 and 3 trials. What does this mean for Anixa. First, Anixa owns a very promising asset and is working with the Cleveland Clinic to develop it. Most importantly, Anixa is not spending money on the development because the DOD is funding this program. It's the best of all possible worlds for Anixa.

https://www.prnewswire.com/news-releases/anixa-biosciences-announces-a-strategic-alliance-and-licensing-agreement-with-cleveland-clinic-for-an-innovative-breast-cancer-vaccine-technology-300886296.html

About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against ?-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

Tiberend Strategic Advisors, Inc.

Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694

Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686

Disclaimer:
We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on this page unless you can afford to lose your entire investment. InvestorNewsSource and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. InvestorNewsSource is compensated by third party shareholders to feature certain companies. These third parties may have shares and may liquidate the company's shares which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Investor News Source may, from time to time, purchase shares of public companies that we have been compensated to feature or profile in the open market and Investor News Source does this at fair market value. Release of Liability: Through use of this advertisement page viewing or using you agree to hold InvestorNewsSource its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the Information. This is not a solicitation to buy stock.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Rochester, NY -- (ReleaseWire) -- 04/04/2020 -- Disability Application Help provides a free nationwide disability benefits evaluation service. A new website has been launched that makes it easier for people to request a free case evaluation. The free service allows disabled people to quickly find out if they may qualify for social security disability benefits. Some people may find that after working many years on the job that their body can't do the work that it once did. An example of a person that may qualify for benefits would be a person that was a roofer for many years and now finds that their knees are in very bad shape. If the person can't find another job because they did only roofing during their career, they may qualify for social security disability benefits.

It's easy for people to request a free case evaluation. A person enters their contact information online and answers a few simple questions. A disability advocate or attorney will review the information and then call the disabled person to ask any additional questions and give the results of the disability benefits evaluation.

Disability Application Help has reliably been providing free social security disability case evaluations since August 2011. Disability Application Help has its headquarters in Rochester, New York.

Disability Application Help welcomes links from other websites to promote the free disability case evaluation service. Visit Disability Application Help at https://www.disabilityapplicationhelp.org.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New York, NY -- (ReleaseWire) -- 12/04/2019 -- SHARE, the national breast and ovarian cancer nonprofit that supports, educates, and empowers women affected by these diseases, is proud to announce Carol Evans as its new CEO and Executive Director. Carol was the Founder and CEO of Working Mother Media and Working Mother magazine, which she led for 25 years. She has been a lifelong advocate of equity and inclusion in the workplace, a champion for women of color, and a spokesperson for women's health issues including breast cancer.

"Carol Evans brings decades of leadership, proven success in growing businesses, and a tireless passion for advocating for women to SHARE. She is well prepared to build on SHARE's strong foundation and to lead us in expanding our mission and our outreach to women in need. We are excited for the innovation and energy she brings to our community," said Angelica Cantlon, SHARE Board President.

"What I appreciate most about SHARE is its network of survivors and women living with breast, ovarian and metastatic breast cancer who volunteer to answer the Helpline, lead our support groups and go into underserved communities to teach the symptoms and signs of these cancers. It's extraordinary to see the circle of women helping women at SHARE. I'm so proud to be a part of this work," said Carol.

Carol has launched many influential initiatives including the Working Mother 100 Best Companies and the Multicultural Women's National Conference. Carol has been a Board member for multiple nonprofits including Vice Chairman of the March of Dimes and President of AWNY. She is Co-Chair of Executive Women for Her, a national volunteer group that supports progressive female candidates, and is the author of This Is How We Do It: The Working Mother's Manifesto, published by Penguin.

Carol succeeds Jacqueline Reinhard, who served as SHARE's Executive Director from 2012-2019, as she retires. Under Jacqueline's leadership, SHARE developed a national reputation for culturally-competent outreach services into medically underserved communities. Jacqueline also led SHARE's national expansion, introducing technological innovations and support services across the country that increased the number of women SHARE serves to 200,000 each year.

"We are deeply grateful to Jacqueline for all that she has brought to SHARE during this time, building an effective foundation for SHARE's future," says Angelica, "and we are excited for Carol to bring her deep experience in advocacy and growth to strengthen SHARE's goal of ensuring that no woman has to face a breast or ovarian cancer diagnosis alone."

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Avalon GloboCare Corp. Is In Perfect Position To Take Advantage Of The Trade Deal After Repurchasing All Of The Company’s Outstanding Warrants

Rochester, NY -- (ReleaseWire) -- 11/13/2019 -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, is poised to take advantage of the Chinese trade deal optimism from last week. Avalon Globocare closed the week on Nov 7th just over even on the week however there was an increase in liquidity from the week before and 3/5 trading sessions closed a green signaling regimen investor optimism.

The recent reports of a trade deal closing by the end of 2019 between the US and China could be a turning point for a number of US listed Chinese and Hong-Kong based companies. Big investors like Black Rock, Charles Schwab and Mellon Corp have all been publicly disclosing they're activity taking or have taken large positions in AVCO from the Q2 quarter up to the end of October.

The lagging chart for AVCO is believed to be entirely related to China/US investment & trade woes but today's White House optimism is a breath of fresh fall air for many who believe in company management and huge revenue potential. AVCO has reached exceptional milestones in 2019 having partnered with GE healthcare, becoming wholly funded by their Chairman in Hong Kong and recently Avalon announced a deal to repurchase 100% its outstanding warrants by Nov 12th. It's mind boggling that a company who has limited it's exposure to short selling by purchasing 100% of its outstanding warrants for the benefit of retail investors is still not getting that the the attention it deserves.

Avalon GloboCare (NASDAQ:AVCO) has successfully initiated human trials in recent months and a company update in this regard its expected in early 2020. The reality is that very smart, very successful market professionals are betting millions of dollars on AVCO and for that reason alone I could recommend that you do your homework. Actually, the list of reasons you should put AVCO on your radar is too numerous to mention in this opinion article so pull it up or contact a financial professional. The CAR-T exosome based cancer treatment is so big that GE sprinted at the chance to partner with AVCO. So it seems that Avalon has the potential to be a breakout company with a trade deal in the bag for the USA.

Recent News:
Avalon GloboCare Enters Agreement to Repurchase 100% of Outstanding Warrants
Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines
Avalon GloboCare Announces $20 Million Credit Facility Provided by Company Chairman

About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of in vitro diagnostics (''liquid biopsy''), immune effector cell therapy (including CAR-T/CAR-NK), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

INS has been paid $3500 as a consultant for this content. Neither INS or myself are licensed stock analysts or a financial advisers of any kind so I we insist that you consider this content only an opinion. You really need to do your own research and please realize that trading stocks in the open market is very risky so you could potentially lose your entire investment. This is not a solicitation to buy or sell stock. Always do your own research and trade at your own risk.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Francisco, CA -- (ReleaseWire) -- 09/12/2019 -- Neuromation Researchers Demonstrate New AI Technique that Dramatically Improves Reliability of Breast Cancer Diagnosis

Neuromation, the San Francisco-based developer of applied artificial intelligence solutions and cutting edge tools for AI developers, is proud to announce that a paper co-authored by two senior members of its research team, Alexander Rakhlin and Sergey Nikolenko, was accepted for publication in the proceedings of I CCV19-VRMI in Seoul, Korea in October.

ICCV, the International Conference on Computer Vision, is the premier international computer vision event globally. VRMI is a workshop at ICCV dedicated to addressing the challenges of visual recognition model development in the medical image domain.

The paper, Breast Tumor Cellularity Assessment using Deep Neural Networks, demonstrates a new technique that dramatically improves the rating reliability for diagnosis of breast cancer over existing techniques known in the literature.

According to the World Cancer Research Fund, Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. There were over 2 million new cases in 2018. In the United States, about 1 in 8 women will develop invasive breast cancer over the course of her lifetime.

According to author Sergey Nikolenko, Chief Research Officer of Neuromation:

"The only definitive way of diagnosing breast cancer is by removing a sample of breast cells for testing, known as a biopsy. In current clinical practice, tumor cellularity, that is the relative proportion of tumor and normal cells of this sample, is manually estimated by pathologists. Currently, this process may take several days before results are available and is prone to errors and low agreement rates between assessors."

According to the paper's lead author, Neuromation researcher Alexander Rakhlin:

"In this work, we evaluated three strong novel Deep Learning-based approaches for automatic assessment of tumor cellularity from post-treated breast surgical specimens. We validated the proposed methods on the BreastPathQ SPIE challenge dataset that consisted of 2395 image patches selected from whole slide images acquired from 64 patients. Compared to expert pathologist scoring, our best performing method yielded a Cohen's kappa coefficient of 0.70 (vs. 0.42 previously known in literature) and an intra-class correlation coefficient of 0.89 (vs. 0.83). Our results suggest that Deep Learning-based methods have a significant potential to alleviate the burden on pathologists, enhance the diagnostic workflow, and, thereby, facilitate better clinical outcomes in breast cancer treatment.

Neuromation is extremely proud that this paper will be presented in October, as October is Breast Cancer Awareness Month, which is an annual campaign to increase awareness of the disease and to help those affected by breast cancer through early detection, education and support. We hope that this important work will eventually contribute to improved treatment and life outcomes for millions of women worldwide.

Media Contact:
Daria Posrednikova
E: dasha@neuromation.io

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Ovarian Cancer Organizations Nationwide Raise Ovarian Cancer Awareness This September with the #IWishIKnew Campaign

New York, NY -- (ReleaseWire) -- 08/27/2019 -- In honor of Ovarian Cancer Awareness Month this September, ovarian cancer survivors and patients are lifting up their voices with the #IWishIKnew social media campaign, which helps educate the public about ovarian cancer symptoms, risks, and screening options. Anyone impacted by ovarian cancer is encouraged to join the campaign in September by posting their knowledge and experiences on Facebook, Twitter, and Instagram using the hashtag #IWishIKnew.

"Many women who have been diagnosed with ovarian cancer have stories of being initially misdiagnosed or misinformed, of feeling isolated or hopeless," says Stephanie Blaufarb, Ovarian Cancer Program Director at SHARE, a national breast and ovarian cancer nonprofit. "#IWishIKnew lets their stories be heard, connecting women with this shared experience and educating the public about ovarian cancer risk factors, symptoms, and screening."

Throughout September, the organizations SHARE, Clearity Foundation, Colorado Ovarian Cancer Alliance, FORCE, Foundation for Women's Cancer, Sandy Rollman Ovarian Cancer Foundation, Steps Through OC, T.E.A.L.®, and others will be featuring statements on social media from ovarian cancer survivors and patients about what they wish they had known about ovarian cancer when they were first diagnosed using #IWishIKnew:

"#IWishIKnew ovarian cancer is not totally silent. It whispers and needs to be heard. Learn the symptoms, the risks, and what you can do to help prevent getting it. Stay educated! Most importantly, don't ignore any symptom, no matter how vague. Listen to your body." – Pam, stage 3C, diagnosed 2004

The American Cancer Society estimates that there will be over 22,000 new cases of ovarian cancer diagnosed in the United States this year. Symptoms of ovarian cancer include bloating, pain in the lower belly, feeling full quickly or having trouble eating, and having to urinate more often or more urgently, but "there is no screening test for ovarian cancer," said Dr. Stephanie V. Blank, Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology, and Reproductive Science at Mount Sinai Health System. "A PAP smear is a screening tool for cervical cancer and does not screen for ovarian cancer."

Anyone impacted by ovarian cancer can join the #IWishIKnew campaign on Facebook, Twitter and Instagram starting September 1, 2019 by using the hashtag to share their experiences or by sharing content from #IWishIKnew collaborators, linked above.

About SHARE
SHARE is a national nonprofit that supports, educates, and empowers women affected by breast or ovarian cancer, with a special focus on medically underserved communities. Learn more at sharecancersupport.org.

About FORCE
No one should have to face hereditary breast and ovarian cancer alone. FORCE is the voice of the HBOC community, providing support, education and awareness to help those facing hereditary breast, ovarian and related cancers know their healthcare options and make informed decisions. The organization is the de facto leader in guiding critical research and policy issues that impact the HBOC community. For more information about FORCE and hereditary breast and ovarian cancer, please visit www.facingourrisk.org.

About FWC
The Foundation for Women's Cancer (FWC) is a 501(c)(3) nonprofit organization dedicated to supporting research, education and public awareness of gynecologic cancers. FWC is the official foundation of the Society of Gynecologic Oncology (SGO). Learn more at foundationforwomenscancer.org.

About Tell Every Amazing Lady®
Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation's mission also known as T.E.A.L.®'s mission is to promote public awareness and education of the signs, symptoms and risk factors of ovarian cancer while providing support to survivors and raising funds for research in order to find a screening test and cure for ovarian cancer. To learn more please visit www.TellEveryAmazingLady.org

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

GE Healthcare joined hands with Avalon to ramp up cell therapy production and thereby streamlines the whole development/commercialization process.

Rochester, NY -- (ReleaseWire) -- 08/01/2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, announced that they have established a strategic partnership with GE Healthcare. The partnership will accelerate Avalon's standardization, automation and bio-production for clinical-grade Chimeric Antigen Receptor (CAR)-T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV) based regenerative therapeutics. The combination of expertise sets the stage for Avalon to be the leader in cellular medicines with the ability to execute on the complete development lifecycle from innovation through bio-production to the delivery and management of treatment at hospitals for patients. This infrastructure and depth of capabilities ensures the successful execution of the company's ongoing clinical trials.

Under this partnership, both Avalon and GE Healthcare will strategically establish automated and standardized GMP cell production capabilities. Avalon will be given access to GE Healthcare's cell processing expertise and products in the form of FlexFactory Cell Therapy platform, FastTrak process development and training services, as well as extensive SOP and validation protocol library.

Article Written by BioSci Capital Partners via Seeking Alpha.

As Buffett said it best, stellar growth companies do not come often. In my years of daily exploration of the bioscience space, I recently encountered a rare investment prospect you should not miss out. The investment gem is Avalon GloboCare (AVCO), a young innovator of the next-generation chimeric antigen receptor - T cell therapy (i.e. CAR-T). Back in 2017, I was quite excited at the CAR-T prospects of Kite Pharma and Juno Therapeutics. And, I am thrilled as Kite and Juno were correspondingly acquired by Gilead Sciences (GILD) and Novartis (NVS) for $11.9B and $9B.

Since cellular therapy evolves at a rapid pace, I now vote my strongest confidence in Avalon's CAR-T. Nonetheless, I'm not the only one who is optimistic about Avalon's precision medicine and diagnostics. For instance, the company recently inked a mega partnership with GE Healthcare (GE). In this research, I'll present a fundamental analysis of Avalon while focusing on the latest partnership development.

About The Company
As usual, I'll deliver a brief corporate overview for new investors. If you are familiar with the firm, I suggest that you skip to the subsequent section. Headquartered in Freehold, New Jersey, Avalon GloboCare is a CellTech company that operates Avactis Biosciences and Genexosome Technologies subsidiaries. Founded in 2016, Avalon is already forging its crown as a leading cell-based technology innovator.

In the Golden Age of CAR-T, Avalon is focused on the development and commercialization of disruptive medicines and diagnostics to serve the strong unmet needs in cancer and other diseases. Using a trident-like approach of Poseidon, the company captures opportunities in three highly promising niches. They include exosomes diagnostics, regenerative medicine, and cellular immunotherapy. I elucidated in the prior research,

Powering the diagnostic portfolio is precision medicine based on "exosomal biomarkers." Accordingly, Avalon is delivering a diagnostic avalanche against oral cancer, nonalcoholic steatohepatitis ("NASH"), leukemia, colorectal cancer, and macular degeneration. Notably, exosomal biomarkers can quickly pinpoint a diagnosis to give physicians an edge against dreaded diseases. In the battle of life and death, I believe that accuracy and precision are of paramount importance. That aside, Avalon is brewing various potential blockbusters, including AVA-101, -201, and -203.

Pipeline Advancement
On June 22, 2019, Avalon announced a highly strategic partnership with GE Healthcare. Under the collaboration, the companies will work together to improve the logistics such as automation and standardization for good manufacturing practice ("GMP"). As a result, this will galvanize Avalon's global cell production capabilities and thereby positioned it to become an undisputed leader in cell-based medicine.

As a subsidiary of General Electric, GE Healthcare provides logistic solutions to healthcare providers and innovators. Their service and product facilitate research and development of advanced therapies and vaccines. As such, GE improves the outcomes for healthcare providers, innovators, and most importantly patients.

With the aforesaid deal, Avalon strategically leverages GE's FlexFactory Cell Therapy platform and FastTrak process development/training services. Moreover, the company has access to GE's standard operating protocol and protocol library for therapeutic development. Furthermore, users can obtain training at GE sites and Avalon's Nanjing Epicon facility. Enthused by the partnership, the GE Global Commercial Enterprise Solution Leader (Angela Chen) remarked,

Cellular medicines as a bio-industry sector have been growing and evolving at a rapid pace during recent years with vast potential to change the way various diseases are managed. GE continues investing in technologies and services aimed at the thriving cellular medicine industry with a firm commitment to making these promising cellular therapeutic modalities accessible through successful industrialization. We are pleased to work with Avalon GloboCare, a global leader in cell-based therapeutics and exosome technology, who share our mission and vision for advancing innovation and delivering automation, standardization, and bio-production solutions for cellular medicines.

In my view, the collaboration is also favorable for GE because it can strengthen its brand through Avalon's extensive clinical network in China through Lu Daopei hospital network. Though Avalon has strong ties to Cornell Medicine, Lu Daopei hospital is just as reputable as Cornell. After all, it was founded by a stellar physician who is held in high regard in China. I believe that medical innovation is now shifting toward the East. And, China is becoming a global leader in serving the world's largest and increasingly wealthy population.

As a ramification, the partnership will galvanize Avalon's capability to answer the strong demand for cell-based therapies worldwide. For instance, the company can now ramp up its supply of clinical-grade cellular products consisting of chimeric antigen receptor (CAR-T), CAR-NK (natural killer cells), and stem cell-derived exosomes. Specifically, it ensures an adequate supply of biological specimens through scale-up manufacturing throughput and efficiency. Moreover, standardization and automation improve the specimen's uniformity.

In growing its clinical and commercialization programs for cellular medicines, it's important for Avalon to have standardization, automation, and uniformity. The GE partnership provides all of that and more. Notably, Avalon is conferred with complete control of the whole development lifecycle. Hence, the company has the helm to fine-tune the innovation process from bench-research to treatment delivery. Consequently, the infrastructure and depth capability of GE ensure the successful execution of ongoing clinical investigations. As he captured the colossal deal in the most poignant terms, the President and CEO of Avalon (David Jin, M.D., Ph.D.) is stoked,

We are pleased to establish this strategic partnership with GE. This is a crucial and exciting time in the evolution of cellular medicines and our combined skills will drive Avalon to move innovation forward and ultimately deliver the best therapeutic solutions for patients. This partnership enables Avalon to more fully leverage and integrate our core technology platforms and accelerate our clinical programs in cellular immunotherapy and stem cell-derived exosome-based regenerative therapeutics. Empowered by GE's leading automation and standardized cell processing/bio-production capabilities, we look forward to further upgrading our infrastructure, services and products, as well as expanding our leadership role in cellular medicines.

I concur with the illustrious Chief, as I believe in GE's centuries of legacy. In my view, it bodes well for shareholders when a young company can entice a highly reputable firm like GE. If the technology is subpar, I highly doubt that GE would be interested. Asides from its uncanny medicines and diagnostics, it's quite likely that Dr. Jin's reputation secured the deal. A larger firm usually works with a strong management who will deliver good results. The cream of the crop leadership improves the chances of successful innovation that in turn enhances the reputation of the partner. I explicated in the prior article,

As a physician and scientist, Dr. Jin provides Avalon an intellectual advantage in pipeline development. Due to his background and expertise, Dr. Jin has the capability to quickly size up a pipeline prospect for its chances of success. Correctly forecasting which drug has the best chance of success can save the company from billions of dollars that otherwise go into unfruitful and lengthy studies. It's interesting to note that Dr. Jin was the CMO of another company BioTime from 2009 to 2016. That experience enabled him to bring his regenerative medicine and stem cell technology expertise to Avalon. That aside, Dr. Jin served as the physician/scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University.

Financial Assessment
Just as you would get an annual physical for your well-being, it's important to check up on the financial health of your stock. For instance, your health is affected by "blood flow" as your stock's viability is dependent on the "cash flow." With that in mind, I'll analyze the 1Q2019 earnings report for the period that concluded on March 31. Notwithstanding, I'll briefly touch on the most insightful metrics because I previously dissected the financials.

As follow, Avalon registered $284.1K in revenues compared to $307.9K for the same period a year prior. That aside, the research and development (R&D) came in at $152.4K. Additionally, there were $4.4M ($0.06 per share) net loss compared to $1.4M ($0.02 per share) decline for the same period of comparison. On the balance sheet, there were $1.8M in cash versus $2.1M for last year. With $6.0M from a direct offering raised back on April 25, the total cash position increased to $7.8M.

Against the $4.4M quarterly operating expense (OpEx) rate, Avalon will likely execute a public offering this quarter. In my observation, investors usually shy away from a public offering. Nevertheless, I prefer a young bioscience company to raise capital this way rather than incurring substantial bank debts. Short-term bank debts can be recalled anytime that can prompt a company to file a Chapter 11. The key to raising capital is to do it when the shares are trading high.

Though I do not mind a public offering, it's important for you to determine if you are holding a "serial diluter." A firm that employs dilution as a "cash cow" will render your investment essentially worthless. As the shares outstanding increased from 69.7M to 73.7M for Avalon, my rough arithmetics yield the 5.6% dilution. At this rate, Avalon easily cleared my 30% dilution cutoff for a profitable investment. Looking at the financial metrics, it's quite clear that Avalon is working for the best interests of the shareholders and patients.

Potential Risks
Since investment research is an imperfect science, there are always risks associated with your stock regardless of its fundamental strength. At this point in its growth cycle, I believe that the main concern is if Avalon can deliver positive data for various franchises. As the bulk value of the company resides in CAR-T, a negative clinical reporting for AVA-101 can cause the stock to tumble over 60% and vice versa. After accounting for all probability, I expect that AVA-101 to deliver excellent results. Therefore, the chances of a negative clinical binary are approximately 35%. The other risk is that the firm might grow aggressively and thereby runs into a potential cash flow constraint. GE can also terminate the partnership, thus limiting Avalon's reach.

Conclusion
In all, I maintain my strong buy recommendation on Avalon Globocare with the five out of five stars rating. On a one to three years horizon, I anticipated the $12.5 price target to be reached. You can read my valuation in the previous note. Due to the GE collaboration, I increased the "investment profitability score" to 70%. In a nutshell, you have a strongly favorable chance of making money on Avalon, provided that you hold the stock for the long haul. As it captures lightning in a bottle, Avalon is growing a prodigious pipeline of precision medicine that includes diagnostics, immunotherapy, and regenerative meds.

Among the countless CAR-Ts that I studied, Avalon's CAR-T is the most advanced. AVA-101 is ingeniously innovated by a Chief who knows the ins and outs of pharmaceutical developments. Going forward, I believe that it will disrupt the oncology space. But that's not all. The diagnostic for NASH or macular degeneration alone can easily garner blockbuster results. Then, there's regenerative medicine and diagnostics to confer additional profits and diversification. With GE's support, Avalon is cementing its leadership in this Golden Age of CAR-T.

Investor News Source Disclaimer:
This report/release/advertisement by Investor News Source and is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: Investor News Source and its employees are not a Registered Investment Advisors, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Everything you see is a paid advertisement and should not be considered financial advice or a solicitation to buy or sell stock. Always contact the financial institution and do your own research before buying any security which is at your own risk. Investor News Source is a digital marketing company located in Cleveland Ohio. Investor News Source was compensated fifty thousand dollars for marketing services By The Company. Never invest in any stock unless you can afford to lose your entire investment. This content is for commercial purposes only.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Avalon GloboCare Corp. announced a strategic partnership with GE Healthcare on July 22. The deal is designed to accelerate Avalon’s standardization, automation and bio-production for CAR-T cells and other cellular therapies related to immunotherapy.

Freehold, NJ -- (ReleaseWire) -- 07/30/2019 -- Avalon GloboCare Corp. (NASDAQ:AVCO) announced a strategic partnership with GE Healthcare (NYSE:GE) on July 22. The deal is designed to accelerate Avalon's standardization, automation and bio-production for CAR-T cells and other cellular therapies related to immunotherapy. This includes exosomes/extracellular vesicles (EV)-based regenerative therapeutics.

Avalon, based in Freehold, New Jersey, is an international biotech developer and healthcare service provider. In addition to its core platforms, Avalon Cell and Avalon Rehab, it provides strategic advisory and outsourcing services to clients in the healthcare market. Its U.S. subsidiary, GenExosome Technologies, focuses on liquid biopsies, precision medicine and regenerative medicine.

Its exosome technology is being designed for early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, as well as treatments for Alzheimer's disease, arthritis, osteoporosis and others. Avalon Cell focuses on cell-based therapies related to in vitro diagnostics, regenerative medicine and cancer immunotherapy.

On July 15, Avalon provided updates on four of its clinical programs in cellular therapy. AVA-001, a CD19 CAR-T candidate, is in a first-in-human clinical trial in China for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin's Lymphoma (NHL).

AVA-101, a transposon-based, multi-targeted CAR-T candidate, is beginning preclinical development and validation and expects to enter the clinic in the first quarter of 2020. AVA-201 is a therapeutic candidate for oral cancer using engineered mesenchymal stem cells as a "bio-factory" to mass-produce miR-185, which suppresses cancer cell proliferation, invasion and migration cell cultures. The resulting miR-185 enriched exosomes, AVA-201, have been applied to oral leukoplakia lesions in animal models in a proof-of-concept study.

And finally, AVA-202 is a clinical-grade, exosome-based therapeutic candidate. The company recently finished its standardized bio-production work that it is co-developing with Weill Cornell Medicine. These exosomes have shown the ability to regenerate tissues, especially blood vessel formation and wound healing. The company plans to get AVA-202 into the clinic in the fourth quarter of this year for vascular diseases and wound healing, including treatment for diabetic foot ulcers.

The company is also commercializing its ACTEX-based product development for skin care, scar removal, and hair growth.

Under the new partnership with GE Healthcare, they will establish automated and standardized GMP cell production capabilities. Avalon will have access to GE Healthcare's cell processing expertise and products by way of FlexFactory Cell Therapy Platform, FastTrak process development and training services. In addition, Avalon will have access to GE Healthcare's SOP and validation protocol library.

Training for these procedures will be performed at both GE Healthcare and at Avalon's Nanjing Epicon GMP facility in China, with the ability to use GE Healthcare's bio-manufacturing resources.

In September 2018, Avalon entered a joint venture with Jiangsu Unicorn Biological Technology Co. called Epicon Biotech Co. It is located within the Nanjing BenQ Hospital, a Grade 3A medical center in Jiangsu Province, China. In June 2018, Avalon established a provincial network of translational cellular therapies and bio-banking programs in China with Jiangsu Unicorn.

The partnership with GE Healthcare provides access to Avalon's clinical network in China and, according to Avalon, "empower Avalon to improve manufacturing throughput and efficiency, alleviate cost burden, and minimize variability in the automated and standardized bio-production process of clinical-grade cellular products (such as CAR-T, CAR-NK, and stem cell-derived exosomes/EV), therefore, accelerating the development of Avalon's clinical and commercialization programs in cellular medicines."

"Cellular medicines as a bio-industry sector has been growing and evolving at a rapid pace during recent years with vast potential to change the way various diseases are managed," stated Angela Chen, GE Healthcare CGT Global Commercial Enterprise Solutions Leader. "GE Healthcare continues investing in technologies and services aimed at the thriving cellular medicine industry with a firm commitment of making these promising cellular therapeutic modalities accessible through successful industrialization."

Chen went on to say, "We are pleased to work with Avalon GloboCare, a global leader in cell-based therapeutics and exosome technology, who share our mission and vision for advancing innovation and delivering automation, standardization and bio-production solutions for cellular medicines."

This is yet another example of the industry's focus on manufacturing for gene and cell therapies. In March, Thermo Fisher Scientific acquired gene and cell therapy manufacturer Brammer Bio for $1.7 billion in cash. Brammer Bio is a contract development and manufacturing organization (CDMO) focused on manufacturing viral vectors for gene and cell therapies.

Also in March, bluebird bio announced it was opening a new gene therapy manufacturing facility in Durham, North Carolina. That factory will produce lentiviral vectors for its gene and cell therapies, including bb2121 and bb21217 for multiple myeloma and possibly LentiGlobin for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease.

In May, Bayer announced plans to build a Cell Culture Technology Center in Berkeley, California, investing $150 million in the project. The center will develop biologics. The facility will be constructed on Bayer's existing campus where its manufacturing currently makes its Factor III hemophilia A treatments. The new Cell Culture Technology Center is expected to open for clinical production in late 2021. The facility will be designed and built by Fluor. GE Healthcare was chosen to integrate its FlexFactory technology platform and supply all major unit operations, systems and ancillary equipment.

"Bayer's Cell Center Technology Center will combine automation, digital capabilities and single-use bioprocessing technologies to streamline production to allow us to bring new medicines to patients faster," stated Judy Chou, senior vice president and Global Head of Bayer Biotech and head of Bayer's Berkeley site. "We've chosen to partner with Fluor and GE Healthcare on the Cell Culture Technology Center to leverage their expertise in designing flexible, scalable facilities for the future."

According to a recent industry report, there are almost 300 gene therapies being developed to treat more than 100 diseases. As these therapies enter clinical trials and eventually the marketplace, the demand for specialized manufacturing capabilities and infrastructure are only likely to increase.

Investor News Source Disclaimer:
This report/release/advertisement by Investor News Source and is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: Investor News Source and its employees are not a Registered Investment Advisors, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Everything you see is a paid advertisement and should not be considered financial advice or a solicitation to buy or sell stock. Always contact the financial institution and do your own research before buying any security which is at your own risk. Investor News Source is a digital marketing company located in Cleveland Ohio. Investor News Source was compensated fifty thousand dollars for marketing services By The Company. Never invest in any stock unless you can afford to lose your entire investment. This content is for commercial purposes only.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New York, NY -- (ReleaseWire) -- 06/19/2019 -- National breast and ovarian cancer nonprofit SHARE is pleased to welcome Angelica Cantlon as the organization's new Board President. Angelica Cantlon is the Founder and Managing Partner at Cantlon & Associates, LLC in New Canaan, CT. She succeeds Ilene Cohen, Senior Vice President at PubWorX, who served as Board President for two terms and will remain on the Board.

"We are deeply thankful to Ilene Cohen for her years of service to SHARE, and we are now delighted to welcome Angelica Cantlon as our Board President. Angelica brings a sincere passion for SHARE's mission, and her immense expertise in global strategy and human capital will help SHARE scale to serve the hundreds of thousands of women facing breast or ovarian cancer in need of support," says Jacqueline Reinhard, SHARE's Executive Director.

Ms. Cantlon is herself a two-time breast cancer survivor. "I feel very privileged to have been offered this opportunity and believe this is a way for me to pay it forward after so many people, both friends and family, were there for me," she says.

From 2009 to 2017, Ms. Cantlon was Executive Vice President, Chief Human Resources Officer, for International Flavors & Fragrances Inc. Prior to joining IFF, Ms. Cantlon spent 10 years at MetLife; her last position was Senior Vice President and International Chief Administrative Officer. She has also held executive HR positions at Morgan Stanley, Orion Capital Companies, Avon Products, and Southern New England Telephone, and has worked for Greenwich Hospital and The American Health Foundation. She is on the Advisory Board of Healthy Children Directions and is a member of the International Women's Forum; she previously was on the Women's Council and Leadership Committee of Lincoln Center. Ms. Cantlon holds a BS with honors from Marymount College and a MA, Omicron Nu, from New York University.

"SHARE has a 43 year foundation of strength, our mission is clear, and we have a deeply knowledgeable staff and amazing volunteers. My goal is to leverage all that has come before and consider how we can reach even more women to lighten their struggle during a time of need. SHARE's Board will continue to strengthen our alliances with other organizations, get the word out on who we are, and enhance our fundraising so that there are more resources to go towards our mission," says Ms. Cantlon.

About SHARE
SHARE is a national nonprofit that supports, educates, and empowers women affected by breast or ovarian cancer, with a special focus on medically under-served communities. Our mission is to connect these women with the unique support of survivors and peers, creating a nationwide community where no one has to face breast or ovarian cancer alone. SHARE's free services, provided in both English and Spanish, include national helplines, support groups, expert-led educational programs, clinical trial assistance, community outreach, corporate education, advocacy opportunities, caregiver support, and survivor-patient navigation.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Local Woman Starts Breast Cancer Outreach for Vulnerable Population

New York, NY -- (ReleaseWire) -- 06/04/2019 -- After realizing her local hospital only offered a single breast cancer support group for Spanish-speakers, local breast cancer survivor Pierre started her own support group in her apartment building, in connection with LatinaSHARE, the Spanish-language division of national cancer nonprofit SHARE. Her next meeting, open to all Spanish-speaking women affected by breast cancer, is June 25. Pierre is also making a targeted effort to perform outreach into Orlando's Spanish-speaking communities.

"I had no family history of breast cancer that I knew of. Women didn't do self-exams at that time. People didn't talk about those things," Pierre says of when she was diagnosed. Eventually she called LatinaSHARE's free Spanish-language breast cancer helpline. Soon, she was volunteering herself as a LatinaSHARE support group facilitator.

After completing treatment in New York, Pierre moved to Orlando. But she missed the connection and fulfillment that came from working with breast cancer patients and survivors. When she discovered the lack of Spanish-language services available to Orlando's Latina population, she took it upon herself to begin filling that need through a support group and outreach.
"I hung a support group flyer up in the local senior center and in my apartment building. And the women just came."

Orlando has a significant Latino population but lacks meaningful access to Spanish-language cancer support services. Research shows that Hispanic women face more barriers to breast cancer care than other ethnicities, including cultural and language issues, lack of childcare or dependable transportation and, being denied sick leave from employers. Lower income or poor health insurance also leads the community to receive fewer mammograms than other women, which means Latina women are often diagnosed at advanced stages that are harder to treat.

"So many obstacles get in the way of Latinas taking care of their breast health, from language barriers to fear," said Jennie Santiago, co-director of LatinaSHARE. "We are so excited to have a presence in Orlando where there are fewer Spanish-language services. This will allow us to continue to empower these women to overcome these obstacles."

Many cancer support groups are led by an LCSW. Pierre's group uses LatinaSHARE's peer model, which trains cancer survivors to lead support groups. "Having a survivor facilitate instead of a social worker helps to put a face on survivorship for women. It helps them realize they can be okay too," says Pierre.

Pierre is now conducting outreach among clinics, hospitals, and community hubs for Orlando's Spanish-speakers to distribute culturally relevant information about breast and ovarian cancer, and is recruiting other women to do the same. Eventually, she'd like to see even more Spanish language services become available in Orlando. "There are so many programs that helped me when I was a patient, like yoga and meditation. I want to be a part of helping to offer more services in Spanish that continue to improve women's health."

Pierre's group is held entirely in Spanish and meets at 350 E. Jackson St. 2-3:30pm, on June 25, July 16, and July 30. Register here or call 212.221.1626.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Ms. Walker is expanding breast and ovarian cancer awareness to African-American and Caribbean women in the five boroughs through NYC nonprofit SHARE

New York, NY -- (ReleaseWire) -- 02/05/2019 -- Desiree Walker, a two-time breast cancer survivor, is determined to eliminate the health gap for African-American and Afro-Caribbean women in underserved NYC communities.

Walker works with SHARE, a New York City-based breast and ovarian cancer nonprofit, as an Ambassador for its African-American Ambassador program, an outreach initiative that trains women of color to educate their communities throughout the five boroughs about breast and ovarian cancer in order to reduce health disparities. She also facilitates its Harlem support group for women of African descent.

It's an agenda that's close to Walker's heart, who was first diagnosed with breast cancer at 38 years old. The illness took her by surprise, as she'd previously regarded breast cancer as an older woman's disease.

"When I was diagnosed, I knew the words "breast" and "cancer" but very little about breast cancer as a disease, which made me feel powerless," Walker says. "As a result, it's been my mission to educate communities, especially women, and empower them if they should ever hear the words 'you have breast cancer.'"

This mission led Walker to SHARE in 2008, where she performed general outreach and facilitated several programs before moving into her current role with SHARE's Ambassador program. SHARE Ambassadors are all women of color, trained to share their experience with cancer in their communities and distribute reliable information about breast and ovarian cancer symptoms, screenings, and potential risk factors at community health fairs, churches, and consulates. In 2018, the Ambassador program reached more than 31,000 women in the five boroughs.

Walker also wants women to know the importance of advocating for themselves, recalling an encounter with an oncologist she believed didn't take her concerns seriously. "Don't be afraid to speak up if something doesn't feel right. It's important that you voice your concerns and feel heard through every step of the journey."

Research has shown significant health disparities for women of color, including different treatment within the medical system. Black women are 42% more likely to die from breast cancer than White women, are often diagnosed with more aggressive cancers at later stages, and do not receive timely follow-up after diagnosis and treatment.

"Women of color face many barriers when it comes to their health," said Ivis Febus-Sampayo, SHARE's Senior Director of Programs. "Outreach like the Ambassador Program is just one way we're working to change that."

Walker also leads a breast and ovarian cancer support group for women of African descent, meeting twice a month in Harlem. The group is an opportunity to connect with other women who are also undergoing the challenges particular to being a woman of color with cancer. "It's a safe space for everyone to be candid and comfortable to share whatever's on their mind without fear of judgment," Walker says.

The SHARE Ambassador Program is funded by the New York City Department of Health and Mental Hygiene, Fashion Targets Breast Cancer Fund in The New York Community Trust, Genentech, and generous SHARE donors. For more information, including how to participate, visit: sharecancersupport.org/outreach/share-ambassadors

The Harlem support group for women of African descent meets at Countee Cullen Library at 104 W. 136th St from 4-5:30pm on March 19 and April 16 and from 5-6:30pm on February 5, March 5 and April 2. Interested participants can register at 212.382.2111.

Community venues looking to schedule an Ambassador presentation or drop-off of materials can contact Dominique Bethea, Outreach Manager, at dbethea@sharecancersupport.org

About SHARE
SHARE is a national nonprofit that supports, educates, and empowers women affected by breast or ovarian cancer, with a special focus on medically underserved communities. SHARE meets women wherever they are with the insight of others who have been there too, creating a nationwide community where no one feels alone. SHARE's free services, provided in both English and Spanish, include support groups, expert-led educational programs, national Helplines, community outreach, online communities, corporate education programs, advocacy opportunities, caregiver support, and survivor-patient navigation.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MyCare Compass, Arches’ Digital Patient Engagement Platform Expands to Include Patients Being Treated with Immunotherapy

New York, NY -- (ReleaseWire) -- 01/29/2019 -- Arches' intelligent software platform is expanding to serve Kettering's immunotherapy patients.

In 2018, Arches launched MyCareCompass at Kettering Health Network with the oncology service line. The goal is to help augment education delivered at the point of care and better prepare patients for their upcoming treatments. Initially the focus was on patients undergoing infusion chemotherapy. This week, Arches launched its second module for immunotherapy patients. Arches and Kettering Cancer Care are planning further development of this program to include oral chemotherapy, surgery and radiation – areas that require extensive preparation and expectation setting.

The expanded MyCareCompass offering delivers critical education based on key appointments in the treatment journey, ensuring the information patients receive is timed for specific milestones. Arches' HIPAA-compliant system architecture integrates with Kettering's EMR (Epic), enabling secure, automated, and real time exchange of diagnosis and treatment data. By automating this process seamlessly with the care center's operations, hospital staff is no longer required to manually input data, significantly reducing administrative burden.

The Kettering Health Network Cancer Care team boasts decades of experience treating all types of cancer with cutting-edge oncology treatments. Central to that is a holistic, patient-focused approach to provide patients and families with critical educational and emotional support. "We know that a cancer diagnosis can be a time of confusion and information flooding for patients and their families," said Elizabeth Koelker, Executive Director of Network Oncology Serviceline at Kettering Health Network. "We are thrilled to partner with Arches Technology to ensure that our patients are receiving the right information, at the right time, through communication mediums that are easily understood. It is our job to make sure patients have a clear understanding of their disease and treatment so they can make informed decisions."

"Arches is excited to expand its partnership with Kettering to include cancer patients being treated with immunotherapy as part of the MyCareCompass value add initiative. This method of 'just in time' education is proven to enhance health outcomes by reducing fear and anxiety in cancer patients, ultimately improving comprehension, compliance and enabling a level of cooperation necessary for treatment to succeed," says Patrick Flavin, President of Arches.

About Arches
Arches develops highly specialized intelligent software products that empower oncology healthcare companies to deepen their relationship with patients. Built specifically for oncology patient engagement, Keystone allows customers to easily test and automate the delivery of personalized health education in a way that encourages responsiveness to real-time behavior. Keystone's interoperable and secure platform leverages patient data points to responsively deploy education and information at key moments in the health journey when they need it most. Through patent-pending AI technology, Keystone helps healthcare organizations optimize their patient outreach and content strategies to ultimately reduce fear, anxiety and administrative burden thus motivating positive behavior and enhanced health outcomes.

Learn more about Arches at: http://www.archestechnology.com.

https://archestechnology.com/arches/mycarecompass.html
Source: Arches Technology

For Arches
Tommy Zambelli
Vice President, Marketing and Customer Success
Email: tzambelli@archestechnology.com

For Kettering
Elizabeth LaForce
Manager, Oncology Access, Kettering Cancer Care
Email: Elizabeth.LaForce@ketteringhealth.org

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Panel discussion hosted by Judges & Lawyers Breast Cancer Alert, SHARE Cancer Support, and Young Survival Coalition will examine transparency and accountability among healthcare institutions, doctors and patients

New York, NY -- (ReleaseWire) -- 01/04/2019 -- Oncologist Dr. Otis W. Brawley, researcher Robert M. Cook-Deegan, and breast cancer advocate Fran Visco will speak on January 10 at a panel discussion moderated by Robert Bazell: "Conflicts of Interest in Research and Treatment: What Breast Cancer Patients Should Know." The event is co-sponsored by SHARE Cancer Support, Young Survival Coalition and Judges and Lawyers Breast Cancer Alert. Free and open to the public, it will explore the growing concerns about how the financial interests of medical professionals and institutions may influence the treatment of patients.

"Trust is an important part of patients' relationship to the medical community," said Jackie Reinhard, SHARE's Executive Director. "We hope that this event will help breast cancer patients and advocates understand how that trust may be compromised by conflicts of interest, and how they can play a role in making positive changes."

The panel takes place in the wake of revelations about medical executives, researchers, and institutions benefitting from undisclosed ties to health and pharmaceutical companies. Panelists will speak to the practical and ethical implications of sponsored research, corporate partnerships, and failures to disclose, and will suggest opportunities for advocacy. They include:

Robert Bazell (moderator), adjunct professor in the Department of Molecular Cellular and Developmental Biology at Yale University. He was the chief science and health correspondent for NBC News for 38 years and is the author of the best-selling book HER-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer (Random House, 1998);

Otis W. Brawley, MD, board-certified oncologist and professor at Johns Hopkins who is regarded internationally as one of the leading experts in cancer treatment and prevention. He served as Chief Medical Officer and Executive Vice-President of the American Cancer Society for 11 years and is the author of How We Do Harm: A Doctor Breaks Ranks on Being Sick in America (St. Martin's Griffin, 2012). In 2018, Dr. Brawley resigned from the ACS over concerns of its fundraising ties to corporations with questionable medical credentials;

Robert M. Cook-Deegan, research professor in the School for the Future of Innovation in Society, and with the Consortium for Science, Policy and Outcomes at Arizona State University. He founded and directed Duke's Center for Genome Ethics, Law & Policy, and has written extensively about science and health policy, and cancer and ethics;

and Fran Visco, Esq, President of the National Breast Cancer Coalition, a grassroots advocacy coalition of more than 600 organizations and tens of thousands of individual members. A leader in many national breast cancer advocacy efforts, she is a member of the Governance Board for the Institute for Clinical and Economic Review (ICER), the nation's independent watchdog on drug pricing.

"We feel these panelists will present a keen insight into the state of the medical community's conflicts of interest and be able to suggest paths forward for advocacy," says Ms. Reinhard.

"Conflicts of Interest in Research and Treatment: What Breast Cancer Patients Should Know" will be comprised of a panel discussion followed by a Q&A. It will take place on January 10, 6-7:30pm, in the Actors Equity Building at 165 W 46th St., 14th Floor, New York, NY 10036. It will be recorded and available post-event on the SHARE website, sharecancersupport.org. Register at: http://bit.ly/2rs9EQe

About SHARE
SHARE is a national nonprofit that supports, educates, and empowers women affected by breast or ovarian cancer, with a special focus on medically underserved communities. Its mission is to connect women wherever they are with the insight of others who have been there too, creating a nationwide community where no one has to face breast or ovarian cancer alone. SHARE's free services, provided in both English and Spanish, include national helplines, support groups, expert-led educational programs, community outreach, online communities, corporate education, advocacy opportunities, caregiver support, and survivor-patient navigation. Learn more at sharecancersupport.org or 844.ASK.SHARE

About Young Survival Coalition
Established in 1998, Young Survival Coalition (YSC) is the premier organization dedicated to young women with breast cancer. Founded by three young survivors, YSC began as a grassroots organization to advocate on behalf of all young women diagnosed with breast cancer to increase their length and quality of life. Based in New York City, with networks nationwide, YSC provides free resources, connections and educational materials so young women with breast cancer feel supported, empowered and hopeful. YSC seeks to educate and influence the medical, research and legislative communities to address breast cancer in young women, and to ensure that no young woman faces breast cancer alone. For more information, visit youngsurvival.org.

About Judges and Lawyers Breast Cancer Alert
Judges And Lawyers Breast Cancer Alert (JALBCA) began in the early '90s to educate the legal community about breast cancer. Today, the judges and lawyers of JALBCA continue that mission by educating members of their profession and harnessing their legal expertise and passion to promote medical, educational, social, and legal services. In supporting services like The Family Center and ScanVan, JALBCA facilitates breast cancer detection for those with little or no medical insurance and brings hope to families in marginalized communities. Fiercely committed to alleviating breast cancer, JALBCA continues to fund educational programs, and family-focused initiatives to improve the quality of life for those affected.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Cites inequity of their tax-free status leading to mountains of endowment money vs contribution to community. Harvard $39 billion, Stanford $26.5 billion, Yale $29 billion.

Pebble Beach, CA -- (ReleaseWire) -- 12/17/2018 -- Rider McDowell is a former journalist and entrepreneur (Airborne, Pine Brothers), turned reluctant cancer research crusader. His son Errol, 18, died in June after a terrible six year battle with medulloblastoma, the most common brain tumor in children. While raising desperately needed funding for a number of university labs (Duke, Stanford, UCSF, Case Western, U of Florida and Harvard) McDowell wondered why the universities themselves, with their tremendous endowments, weren't stepping up to the funding plate. "Here is Stanford with a $26 billion endowment, and I'm beating the bushes raising money, sometimes in small amounts, so their researchers can pursue the brilliant potentially curative science they live for, and that so many desperate families long for." According to McDowell, sometimes it takes very little. One $25,000 donation from the McDowell family, directly led to research at Duke, using the Polio virus against Medulloblastoma. The results have been positive, and a potentially curative clinical trial is underway with sick children. Funding from the McDowells and money raised through their late son's charity, Canceragogo.com, has also advanced the fight against pediatric brain tumors at UCSF, Case Western University, U of Florida, and Stanford. Canceragogo.com, which Errol created with his two younger brothers, has raised close to $1 million dollars, much of this raised $1 dollar at a time.

"It seems obscene that these great universities (Harvard $39 billion, Duke $7.5 billion, Stanford $26.5 billion, et al) should sit on the mountains of endowment money, raised tax-free from the public, and not feel compelled to make the money work towards the betterment of this same public, in this case the fight against cancer. McDowell sites the panoply of tax breaks these schools also receive, including not paying property taxes; which McDowell calls an in-kind donation from the community where the school resides. McDowell feels that, concomitant with the tax free status, a percentage of the amassed endowments should be mandated to be spent on medical research. "Certainly these schools do a lot of good, including building the labs in question, but their relatively stingy and desultory largess, subsidized by the American taxpayer, should benefit these taxpayers more directly. "

McDowell calls it naive to rely on the government alone to cure society's medical ills. "Researchers spend between 1/4 to 1/2 of their time on paperwork pursuing NIH grants, and then more time on paperwork to comply with the grants. The NIH, meanwhile, funds only 6% of all grant requests, due to budget restraints. This means that roughly 94 percent of all grant requests are denied." As a result of this "flawed paradigm," says McDowell, potentially life-saving clinical trials for cancer treatments often never see the light of day. McDowell has been talking to researchers at Harvard's Dana Farber about a cutting edge cancer vaccine and ground breaking stem cell research. "They are desperately seeking $250,000 for research and pre-clinical trials. Yet Harvard's endowment is at $39 billion. $250,000 is less than one half hour's worth of interest on their endowment. And that's criminal."

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (ReleaseWire) -- 11/26/2018 -- Stomach cancer kills, it kills mercilessly, it kills young and old, it kills men and women. Yet there is very little awareness about this orphan cancer.

According to the World Health Organization's September 2018 report, stomach cancer is the third leading cause of cancer related deaths in the world; more than breast cancer and liver cancer. It is estimated that in 2018 stomach cancer alone will cause 8% of the 9.6 million cancer related deaths in the world.

On November 30, Stomach Cancer Awareness Day, My Gut Feeling – Stomach Cancer Foundation of Canada aims to stop the silence. The only non-profit, volunteer-run organization in Canada, founded by two survivors, and dedicated to supporting patients, survivors and caregivers, is holding its 2nd Annual Stomach Cancer Conference in Toronto, Canada. The conference will bring together those going through the stomach cancer journey and some of the medical leaders in gastric cancer to open dialogue, learn from each other and raise awareness. This conference will be live-cast.

My Gut Feeling's awareness campaign, The Power of Periwinkle, will stop the silence on stomach cancer. For the second year, city halls and landmarks across Canada and beyond will light up in periwinkle blue – the color of stomach cancer in order to raise awareness for this deadly disease. We will stop the silence on stomach cancer, we will make our voices heard.

INFO AT A GLANCE
WHAT: Stomach Cancer Awareness Day

WHERE: 2ND Annual Conference: Mount Sinai Hospital,
600 University Avenue, Toronto, Canada
Power of Periwinkle Lightings: Various cities across Canada

WHEN: Friday, November 30th, 2018
WHO: Teresa Tiano, Chair & Co-Founder
Katy Kosyachkova, Vice-Chair & Co-Founder

INFORMATION OR INTERVIEWS: Email: info@mygutfeeling.ca
INFORMATION ON PERIWINKLE LIGHTING LOCATIONS & TIMES: https://mygutfeeling.ca/mgf365

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (ReleaseWire) -- 11/20/2018 -- On Friday, November 30th, Stomach Cancer Awareness Day, My Gut Feeling – Stomach Cancer Foundation of Canada will continue its mission to raise awareness for one of the deadliest cancers.

The only not-for-profit organization dedicated to stomach cancer was co-founded in 2016 by Teresa Tiano and Ekaterina Kosyachkova, two survivors, because "stomach cancer is such a lonely disease, you may have the most supportive family and friends, but to truly understand the physical, emotional and psychological toll of cancer you need to have support from people that have gone through it. We do what we do so that nobody has to go through stomach cancer alone."

The Foundation provides peer-to-peer support for patients, survivors and caregivers and works to educate and raise awareness of the disease and available treatment options from coast to coast.

This year Stomach Cancer Awareness Day will see the Foundation presenting its 2nd Annual Stomach Cancer Conference at Mount Sinai Hospital in Toronto. The day will bring the patient community and leaders from the medical community together in order to educate, raise awareness and open dialogue.

My Gut Feeling's national awareness campaign, the Power of Periwinkle will have city halls and landmarks across Canada light up in periwinkle blue to raise awareness for this disease, that has a five-year net survival rate of 25% in this country, and is the third leading cause of cancer related deaths in the world.

INFO AT A GLANCE
WHAT: Stomach Cancer Awareness Day

WHERE: 2ND Annual Conference: Mount Sinai Hospital,
600 University Avenue, Toronto, Canada
Power of Periwinkle Lightings: Various cities across Canada

WHEN: Friday, November 30th, 2018
WHO: Teresa Tiano, Chair & Co-Founder
Katy Kosyachkova, Vice-Chair & Co-Founder

INFORMATION OR INTERVIEWS: Email: info@mygutfeeling.ca
INFORMATION ON PERIWINKLE LIGHTING LOCATIONS & TIMES: https://mygutfeeling.ca/mgf365

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The first of its kind, the TalkMets/Tuesday Helpline will connect callers with Stage IV breast cancer directly with a metastatic peer

New York, NY -- (ReleaseWire) -- 11/08/2018 -- National breast and ovarian cancer nonprofit SHARE Cancer Support is launching the first dedicated Metastatic Breast Cancer Helpline program, called TalkMets/Tuesday, this November. TalkMets/Tuesday will allow metastatic callers to SHARE's Breast Cancer Helpline (844.ASK.SHARE) to use extension "6" to be assured that the person who answers their call is also living with metastatic breast cancer and has been trained to offer empathetic support, reliable information, and a listening ear.

"Women with metastatic disease often feel excluded by the wider breast cancer community," says Victoria Goldberg, a SHARE Helpline volunteer living with metastatic breast cancer. "We have different needs that are not necessarily served by programs geared toward early stage breast cancer."

According to the Metastatic Breast Cancer Alliance, virtually all of the 40,000 deaths from breast cancer in the U.S. each year occur as a result of metastatic breast cancer, (also called MBC or Stage IV disease) which begins in the breast and spreads to other parts of the body. It is progressive and incurable, and the median survival rate after diagnosis is just three years, though some women live longer.

"SHARE's dedicated Metastatic Helpline, TalkMets/Tuesday, recognizes our differences and makes them a priority," says Ms. Goldberg.

TalkMets/Tuesday is part of SHARE's unique metastatic breast cancer program, which touches lives 23,000 times each year through 15 monthly telephone and in-person support groups, including a Spanish-language group and a group for young women, an annual conference, roundtable discussions, exercise classes, and educational programs on practical and clinical topics.

"Our program participants tell us that the support and camaraderie they receive from women who share their diagnosis is invaluable," says Christine Benjamin, Breast Cancer Program Director at SHARE. "Many women living with metastatic disease have never met anyone else with MBC, so it can be especially meaningful for them to connect with someone who understands it firsthand."

SHARE's all-stage Breast Cancer Helpline (844.ASK.SHARE), available seven days a week, provides 6,000 women with compassionate peer support every year. Started in 1977 by a group of breast cancer patients, it continues to be staffed entirely by trained breast cancer peers. It is available in 19 languages. Callers with metastatic breast cancer who wish to speak to a peer on days other than TalkMets/Tuesdays can ask to be specially matched.

TalkMets/Tuesday is available beginning November 6, 2018 every Tuesday from 9:30am-9pm ET at 844.275.7527 ext. 6.

About SHARE
SHARE is a national nonprofit that supports, educates, and empowers women affected by breast or ovarian cancer, with a special focus on medically underserved communities. SHARE meets women wherever they are with the insight of others who have been there too, creating a nationwide community where no one feels alone. SHARE's free services, provided in both English and Spanish, include support groups, expert-led educational programs, national Helplines, community outreach, online communities, corporate education programs, advocacy opportunities, caregiver support, and survivor-patient navigation.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Record Number of Attendees and Presentations

Charlottesville, VA -- (ReleaseWire) -- 10/31/2018 -- The 6th International Symposium on Focused Ultrasound was held this past week in Reston, Virginia, demonstrating the field's immense progress and the groundbreaking technology's potential to transform medical therapy worldwide. More than 450 clinicians, scientists, government employees and industry representatives from around the globe gathered October 21–25 to hear 250 presentations on the latest research, including key clinical milestones for neurological indications such as brain tumors, epilepsy, Parkinson's disease, Alzheimer's disease, OCD, and depression, as well as recent progress in veterinary medicine.

"Every other year this meeting brings together hundreds of people from all areas of the globe who share a vision that focused ultrasound will – not might – improve the lives of millions of people around the world with serious medical disorders, and each time we meet we are closer to that goal," said Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation. "Since our first Symposium 10 years ago we have seen the technology, and the field, grow from single digits across the board to now: 100 clinical indications and counting, 18 different mechanisms of action, more than 20 worldwide approvals, 550 commercial treatment sites, and at least 100,000 patients treated. This astonishing progress is the result of the hard work, dedication and innovation of those who gathered in Reston this past week, and we are proud to provide a forum for sharing knowledge and fostering collaboration among this group of pioneers and scholars of focused ultrasound."

Symposium Highlights
Through plenary sessions, panel discussions, poster presentations and technical exhibits, researchers shared the latest data on focused ultrasound applications for the brain, cancer immunotherapy, liver, lung, veterinary medicine, and more. Highlights include:

- Brain: Taiwan-based NaviFUS has developed a novel focused ultrasound system guided by neuro-navigation which obviates the need for MR scanning during treatment. It features a multi-channel phased array with focal steering from a commercially available navigation system. The presentation explained the concept of neuro-navigation and shared data on the system's design, performance, preclinical validation and potential clinical applications. For more information: NaviFUS: A Neuronavigation-Guided Focused Ultrasound Device for Clinical Transcranial Brain Application
- Cancer Immunotherapy: Physicians at the University of Virginia have initiated the first US clinical trial combining a cancer immunotherapy drug with focused ultrasound. Led by Dr. Patrick Dillon, the pilot trial combines pembrolizumab therapy with focused ultrasound in an effort to elicit immune stimulation and antitumor effects at local ablation sites and distant non-treated sites. The presentation included preliminary data on the first five patients enrolled in the trial. For more information: Focused Ultrasound Therapy Combined with Pembrolizumab in Metastatic Breast Cancer
- Liver: Dr. Joan Vidal-Jove presented data using high-intensity focused ultrasound (HIFU) to treat 40 cases of primary and metastatic liver cancer at two hospitals in Barcelona (the HIFU Ablation Oncology Unit of Hospital University Mutua Terrassa and the Interventional Oncology group of Institute Khuab's Comprehensive Tumor Center). This study included the first patients treated using histotripsy instead of thermal ablation. The presentation also discussed considerations for the role of hepatic tumor ablation in the present oncology environment. For more information: Focused Ultrasound with Ultrasound Guidance in Liver Cancer as Suitable Option for Lesions in Difficult Locations
- Lung: A research group in Gera, Germany, led by Dr. Frank Wolfram has pioneered a focused ultrasound technique for treating lung cancer that is soon to be translated to the clinical setting. In anticipation of the upcoming clinical trial, the team reviewed data from 200 patients with inoperable lung tumors to determine the percentage that might be possible to access with focused ultrasound. For more information: Towards FUS for Lung Cancer, Which Patient Group with Primary or Secondary Lung Cancer is Preferably Accessible?
- Veterinary Applications: The Oklahoma State University veterinary team led by Dr. Ashish Ranjan presented data from their experience treating tumors and non-healing wounds with focused ultrasound in dogs. They then compared the canine tumor types and sites with those in humans to suggest promising uses for focused ultrasound. For more information: Treating Solid Tumors and Non-healing Wounds in Veterinary Patients with Focused Ultrasound

A Symposium summary document will be made available in the coming weeks, and videos of the plenary sessions and special presentations will soon be available at www.fusfoundation.org.

About Focused Ultrasound
Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. The fundamental principle is analogous to using a magnifying glass to focus beams of sunlight on a single point to burn a hole in a leaf. Where each individual beam passes through the tissue, there is no effect. But, at the focal point, the convergence of the multiple beams of focused ultrasound energy results in many important biological effects, creating the possibility of treating a variety of medical disorders. Focused ultrasound is approved in the United States to treat essential tremor, uterine fibroids, pain from bone metastases, and the prostate. Additional indications are approved outside of the US. The technology is in various stages of research and development for more than 100 diseases, including Alzheimer's disease, Parkinson's disease, hypertension, and tumors of the brain, liver, breast, and pancreas. For more information go to www.fusfoundation.org.

About the Focused Ultrasound Foundation
Based in Charlottesville, Virginia, the Focused Ultrasound Foundation is a tax-exempt, high-performance, entrepreneurial service organization with a global reach. The Foundation seeks to leverage its trusted third-party position through contributing financial and human resources to foster collaboration, to build knowledge and to streamline the process and overcome barriers. The Foundation is on the leading edge of the venture philanthropy and social entrepreneurship movements and has become a model of how donor funding can be used to bridge the gap between laboratory research and widespread patient treatment. The Foundation was recently included in Charity Navigator's list of America's 10 Best Medical Research Organizations.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Windsor, ON -- (ReleaseWire) -- 10/12/2018 -- More than 14 million people hear the words, "you have cancer," each year —nearly half are women.

While their care team prepares them for the medical side effects of cancer treatment, women are left to deal with too many of the physical and appearance-related effects on their own. Cancer often affects all aspects of a woman's body, from their skin to hair to nails, and many deal with additional complications from mastectomies and other surgical procedures.

Healing Pretty,authored by Jackie Apostol-Pizzuti, owner of the Wigs to Wellness cancer care boutique in Windsor, Ontario, addresses the questions and concerns women cancer patients have but don't know who to turn to for answers. In a best-friend tone, Jackie offers the same advice and lessons in the book that she does to her in-person clients. Chapters range from how to deal with hair loss, preventing infections, skin & nail care, chemo brain (cognitive impairment of chemotherapy) and much more. Advice comes not only from Jackie, but from women cancer survivors sharing their stories — called Soul Sisters in the book.

Healing Pretty offers over 300 tips, resources and shopping guides, all in a purse-sized book women can easily take with them to appointments and shopping for wigs, mastectomy bras and more. In addition, Healing Pretty is professionally researched and cited, so women can be confident of the medically-sound advice it offers.

Healing Pretty's Indiegogo campaign focuses on finalizing the design and content of second edition, printing copies at volume discounts to pass on the savings to cancer patients, and providing free copies to those in financial need and to non-profit organizations and cancer centers across North America.

Backers can choose from a range of perks including price discounts on Healing Pretty, Skype consultations with the author, memorial dedications and boxes of books delivered to the organization of their choice.

The Indiegogo campaign runs until October 30, 2018, and you can learn more here: https://igg.me/at/Healing-Pretty.

About Jackie Apostol-Pizzuti
Jackie Apostol-Pizzuti has helped thousands of women heal from cancer with dignity. A licensed hair stylist for over 25 years and the owner of Wigs to Wellness and The Mastectomy Boutique, she started thinking about writing a book after seeing the stress her clients were going through, coming to her filled with anxiety and questions. With no comprehensive book or resource to give them or point to, she created a one-stop resource with information, tips, ideas, and inspiration she gathered from her years of expertise, research and directly from clients. Jackie is also a licensed wig specialist and certified mastectomy fitter.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Hudson Regional Hospital is excited to present the inaugural Breasts & Brunch event on October 27-28 from 10:00 am -- 1:00 pm.

Secaucus, NJ -- (ReleaseWire) -- 10/12/2018 -- As the Indian summer fades and October rustles in, it can almost seem like breast cancer awareness is ubiquitous to every part of our lives. Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among women. While one in eight women in the United States will be diagnosed with breast cancer in their lifetimes, with Ashkenazi Jews the rate is higher. Some specific changes, or mutations, in BRCA1 and BRCA2 genes, occur more frequently in Ashkenazi Jews than in the general population.

However, early screenings and leading a healthy lifestyle are essential. With proactive early screenings, breast cancer is very treatable. According to the American Cancer Society, the five-year survival rate is 99 percent when found early and confined to a localized area.

Further, Hudson Regional Hospital provides a range of different examination and treatment options that can be used for preventing many cancers, especially breast cancer. Based on the most recent data and input from Hudson Regional Hospital physicians, here is a selection of breast cancer prevention tools that can be applied during all phases of life.

Look for the Signs of Breast Cancer

Sometimes the best prevention method is literally to take matters into your hands and perform a self-examination. You can look out for some of the signs and symptoms of breast cancer on their own. A few things you should be looking out for in self-examination are scaly, red or swollen skin near the breast, a lump or thickening near the breast, a change in the size or shape of the breast or dimpling or puckering of skin near the breast. When performing a self-examination, keep notes so that you can review with a health professional.

Mammographies

Hudson Regional Hospital uses the latest x-ray and 3D digital imaging technology to test women for breast cancer. Traditional mammography produces just two images of each breast, a side-to-side view, and a top-to-bottom view. 3D mammography produces many X-ray images of the breasts from multiple angles to create a digital 3-dimensional rendering of internal breast tissue. Research suggests that radiologists can more accurately interpret results from 3D mammography in dense breast tissue, which can lead to fewer false-positive and false-negative readings.

Regarding preventive health, we recommend women receive a mammography annually, starting when they are 45. You can begin to have a mammography every other year after turning 55. In the last 20 years, mammographies have helped reduce the breast cancer mortality by 40 percent.

Healthy Living

Not only important for your overall health but leading a healthy lifestyle can help prevent breast cancer. A few methods to live a healthy life include eating five to six servings of fruits and vegetables a day, get physical activity and maintaining a healthy weight. In addition, limit your alcohol intake and either quit smoking or don't smoke at all.

Learn with Us

Hudson Regional Hospital is dedicated to building a healthier community, and we foster this community through educational events and seminars. On the weekend of October 27-28, we are holding an inaugural breast cancer brunch. This event will feature free breast cancer screenings, women's health and information presentations and a free brunch. The event will last from 10:00 a.m. to 1:00 p.m. both Saturday and Sunday. If you would like to RSVP for our event, please visit our website or call 201-392-3278. Feel free to invite your friends; space is limited.

Hudson Regional Hospital offers these preventive services and others, both on an inpatient and outpatient basis. Patients can inquire about these services or schedule appointments by contacting the hospital directly, either via telephone at 201-392-3100, or email at info@hudsonregionalhospital.com. Patients facing medical emergencies should proceed directly to the emergency room. The emergency room contact number is 201-392-3210.

For a tour of the new Hudson Regional Hospital or to meet the owner and executive staff, physicians should call George Matyjewicz at 201-392-3436 or email GMatyjewicz@HudsonRegionalHospital.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Our Panel of Experts will share tips and strategies for Self Care, Health Crisis, Time Management, Cancer Prevention and Financial Planning

New York, NY -- (ReleaseWire) -- 10/05/2018 -- Women of today have a lot on their plate. Many of us are running a household, taking care of a spouse or significant other, children, and possibly aging parents on top of running a business or having a full-time job. Our health, wellness and self-care often comes last and we forget to take care of ourselves. How can we run businesses and prioritize what is important? How do we plan for unexpected major life events like a serious health diagnosis or a disability? If you're interested in learning how to balance your Health and Wellness while also operating and growing your business, then join Light of Gold PR at our Gold Women's Wellness Business Breakfast to be held on Thursday, October 11th from 8:30am -10:30am at The Brooklyn Chamber of Commerce, located at 335 Adams Street, Suite 2700, Brooklyn, New York, 11201. The Event also includes Breakfast Refreshments, Prize Drawings, and a Fun Speed Networking Session that starts at 8:30 am.

The event is presented in partnership with the New York Life Insurance in honor of Breast Cancer Awareness Month. The two-hour program will feature Panel Experts that specialize in, making the time to tend to your overall wellness and how to prepare as well as manage yourself and your environment in crisis situations. The responsibilities involved in running a business can be made even more complicated when issues of health and imbalance are introduced into the equation. Not only will the business topics be addressed, but the importance of health and wellness as it pertains to work/life balance. The impact of illness in the workplace, health crisis management for entrepreneurs will be covered and is especially important to Dixon-Anderson, herself being a recent breast cancer survivor who found herself going through Chemotherapy and Radiation, while also running her business. "I never thought I would have personal experience with Health Crisis Management but now I do and I encourage Entrepreneurs to create a Health Crisis Management Plan. It's something our Firm had to create very quickly, but it's been critical for us to continue managing our business."

The Panel Experts Include:

Debra Dixon-Anderson, Founder and CEO of Light of Gold PR and The Staying True Brand You Program

Liz Santiago of Celebritay, Health/Wellness & Nutrition Expert

Marlon Altoe of New York Life Insurance Company, Financial Expert

Debra Dixon-Anderson shared,"My journey has been a long and bumpy ride. I was diagnosed with breast cancer in October 2017. The Gold Women's Wellness Business Breakfast is in honor of breast cancer awareness month and this is an event I am super excited to be a part of. I had to incorporate my Self Care, Health and Crisis management into my schedule, and that included going to Chemo and Radiation Treatments, as well as Running my own Business. With my diagnosis I chose to share this journey and I'm looking forward to sharing tips and tools to help anyone who is going through health crisis or anyone who wants to think ahead an plan for a Serious Health Diagnosis"

Liz Santiago says, "Self Care, Nutrition, Healthy Eating, and Fitness, are all very vital components of being your best self. The Gold Women's Wellness Business Breakfast is an important event to be apart of because it is breast cancer awareness month."

Marlon Altoe said, "There is a business side of preparing for a Serious Illness from the Insurance to the Financial Planning, and the Gold Women's Wellness Business Breakfast is a great platform to give tips on these subjects."

To register for the event, visit http://www.goldbusinessconnect.com/calendar-1.html or go to goldbusinessconnect.com and click Calendar. The Early bird special is only $25 and is running now, but will be ending soon! For more information, feel free to email us at info@lightofgoldpr.com or call us at 212-786-6838 or 917-385-1079. We are offering a 50% discount off tickets to anyone currently in Treatment for Breast Cancer.

About Light of Gold PR, Marketing, and Consulting LLC
Light of Gold PR, Marketing, and Consulting LLC sheds light on the gold that exists in organizations, businesses, and individuals. It exposes the hidden treasures that exist in an organization and brings these treasures to light through public relations, marketing, brand management, media relations, promotions, Writing and Content, Web Development, Digital and Technology. Our Staying True to Brand Program was designed to teach businesses and individuals how their business image relates to their target audience, as well as how to stand out from other companies and professionals. Light of Gold PR, Marketing, and Consulting's No. 1 goal is to position its clients for success.

For more information, please visit http://www.lightofgoldpr.com and http://www.stayingtruetobrandyou.com.

Contact: Debra Dixon-Anderson, Light of Gold PR, Marketing, and Consulting LLC
Email: info@lightofgoldpr.com and mediainquiries@lightofgoldpr.com
Phone: 212-786-6838 – NY office or 917-385-1079
Website: http://www.lightofgoldpr.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New York, NY -- (ReleaseWire) -- 08/29/2018 -- September is Ovarian Cancer Awareness Month. The American Cancer Society estimates one in 78 women will be diagnosed with ovarian cancer in their lifetime. In the United States alone, there will be over 22,000 new cases of ovarian cancer diagnosed this year and over 14,000 women will die from the disease. Ovarian Cancer Awareness Month is an opportunity for organizations and people to spread awareness and education about ovarian cancer.

This year, the Foundation for Women's Cancer (FWC), SHARE Cancer Support, National Ovarian Cancer Coalition (NOCC) and Tell Every Amazing Lady (T.E.A.L.®) are collaborating on a national social media campaign featuring the voices of real people. Survivors, patients, medical staff, advocates and friends are encouraged to post messages about what they want the public to know about ovarian cancer using #IWishIKnew throughout the month.

"I was diagnosed with ovarian cancer and BRCA2. My family was tested soon after, and now we know they all carry the BRCA2 gene and they can monitor and minimize their risk. Genetic testing is so important." – Mary Beth, stage 3C, diagnosed 2013

Ovarian cancer has been called the "silent killer" because its symptoms were thought to be undetectable until it reached the later stages. Recent studies have shown the following symptoms are much more likely to occur in women with ovarian cancer than women in the general population:

- Bloating
- Pelvic or abdominal pain
- Trouble eating or feeling full quickly
- Feeling the need to urinate urgently or often

"Ovarian cancer is not totally silent. It whispers and needs to be heard. Learn the symptoms, the risks, and what you can do to help prevent getting it. Stay educated! Most importantly, don't ignore any symptom, no matter how vague. Listen to your body." – Pam, stage 3C, diagnosed 2004

Aside from sharing knowledge and creating a sense of community, this campaign serves as a reminder not to ignore even minor symptoms and to seek a gynecologic oncologist who can manage cancer care from diagnosis to completion of treatment.

"Women diagnosed with this disease are living longer, and some of us have not recurred. We have actually survived to hear gynecologic oncologists use the word 'cured' for late-state ovarian cancer. Miraculous." – Andrea, stage 3C, diagnosed 1996

Learn more about the #IWishIKnew campaign and how to get involved at iwishiknewovca.com.

About FWC
The Foundation for Women's Cancer (FWC) is a 501(c)3 nonprofit organization dedicated to increasing research, education and awareness about gynecologic cancer risk, prevention, early detection and optimal treatment. The FWC is the official foundation of the Society of Gynecologic Oncology (SGO). Learn more at foundationforwomenscancer.org.

About SHARE
SHARE is a national nonprofit that supports, educates, and empowers women affected by breast or ovarian cancer, with a special focus on medically underserved communities. Learn more at sharecancersupport.org.

About NOCC
The mission of the National Ovarian Cancer Coalition (NOCC) is to save lives by fighting tirelessly to prevent and cure ovarian cancer and to improve the quality of life for survivors. Learn more at ovarian.org.

About T.E.A.L.®
Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation's mission is to promote public awareness and education of the signs, symptoms and risk factors of ovarian cancer, while providing support to survivors and raising funds for research in order to find the cure for ovarian cancer. Learn more at tealwalk.org and telleveryamazinglady.org.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm